Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort

被引：0
|
作者：
Sakai, A. [1 ]
Yoshioka, I. [1 ]
Shibuya, K. [1 ]
Hanaoka, T. [2 ]
Ando, T. [3 ]
Hirano, K. [4 ]
Watanabe, T. [1 ]
Kajiura, S. [5 ]
Takahashi, K. [2 ]
Sawada, S. [6 ]
Bando, T. [7 ]
Tohmatsu, Y. [1 ]
Kimura, N. [1 ]
Igarashi, T. [1 ]
Miwa, T. [1 ]
Hojo, S. [1 ]
Matsui, K. [1 ]
Okumura, T. [4 ]
Yasuda, I. [5 ]
Fujii, T. [4 ]
机构：
[1] Univ Toyama, Acad Assembly, Fac Med, Dept Surg & Sci, Toyama, Japan
[2] Univ Toyama, Acad Assembly, Fac Med, Dept Internal Med 3, Toyama, Japan
[3] Univ Toyama, Fac Med, Dept Gastroenterol & Hematol, Toyama, Japan
[4] Univ Toyama, Acad Assembly, Fac Med, Dept Surg & Sci, Toyama, Japan
[5] Univ Toyama, Dept Internal Med 3, Toyama, Japan
[6] Itoigawa Gen Hosp, Dept Surg, Itoigawa, Japan
[7] Saiseikai Toyama Hosp, Dept Surg, Toyama, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.244
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-189
引用
收藏
页码：S164 / S164
页数：1
相关论文
共 50 条
  • [1] The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
    Su, Yung-Yeh
    Chiang, Nai-Jung
    Tsai, Hui-Jen
    Yen, Chia-Jui
    Shan, Yan-Shen
    Chen, Li-Tzong
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [2] Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
    Yung-Yeh Su
    Nai-Jung Chiang
    Hui-Jen Tsai
    Chia-Jui Yen
    Yan‐Shen Shan
    Li‐Tzong Chen
    Scientific Reports, 10
  • [3] Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma
    Kim, George P.
    Surinach, Andy
    Corvino, Frank A.
    Cockrum, Paul
    Belanger, Bruce
    Abushahin, Laith
    FUTURE ONCOLOGY, 2021, 17 (06) : 675 - 688
  • [4] Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
    Koeller, Jim
    Surinach, Andy
    Arikian, Steven R.
    Zivkovic, Marko
    Janeczko, Patrick
    Cockrum, Paul
    Kim, George
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [5] Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
    Yoo, Changhoon
    Im, Hyeon-Su
    Kim, Kyu-pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoungjoo
    Kim, Ilhwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [6] Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
    Gupta, Amol
    De Jesus-Acosta, Ana
    Zheng, Lei
    Lee, Valerie
    Kamel, Ihab
    Le, Dung
    Pishvaian, Michael
    Laheru, Daniel
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study
    Yasuoka, Hidetoshi
    Naganuma, Atsushi
    Kurihara, Eishin
    Kobatake, Tsutomu
    Ijima, Masashi
    Tamura, Yuki
    Suzuki, Yuhei
    Hoshino, Takashi
    Ishida, Fumiya
    Hosaka, Hisashi
    Hatanaka, Takeshi
    Yoshida, Sachiko
    Aihara, Ryusuke
    Hosouchi, Yasuo
    Ishii, Norihiro
    Araki, Kenichiro
    Shirabe, Ken
    Uraoka, Toshio
    Kakizaki, Satoru
    ONCOLOGY, 2022, 100 (08) : 449 - 459
  • [8] Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
    Abushahin, Laith, I
    Cockrum, Paul
    Surinach, Andy
    Belanger, Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
    Yu, Kenneth H.
    Cockrum, Paul
    Surinach, Andy
    Lamarre, Neil
    Wang, Shu
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
    Gupta, A.
    Laheru, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S921 - S921
12345